Martin Alan Menter (A Menter, Alan Menter)

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 17

Top Topics

Top Venues

Dermatology and therapy

Journal of the European Academy of Dermatology and Venereology : JEADV

Proceedings (Baylor University. Medical Center)

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (5) (2024)
Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (5) (2024)
Martin Alan Menter, Tina Bhutani, Benjamin Ehst, Boni Elewski, Abby Jacobson
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatology and therapy 12 (6) (2022)
Martin Alan Menter, Stanley Cohen, Jonathan Kay, Vibeke Strand, Alice Gottlieb, Stephen Hanauer, Sravan Kumar Eduru, Susanne Buschke, Benjamin Lang, Karl-Heinz Liesenfeld, Jennifer Schaible, Dorothy McCabe
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. American journal of clinical dermatology 23 (5) (2022)
Marcus Zaayman, Annika S Silfvast-Kaiser, Edgar Rodriguez, Andrew J DeCrescenzo, Martin Alan Menter
Penile calciphylaxis with extragenital gangrene. Proceedings (Baylor University. Medical Center) 34 (3) (2021)
Aaminah Faheem Azhar, Marcus Zaayman, Annika S Silfvast-Kaiser, Dario Kivelevitch, Martin Alan Menter, So Yeon Paek
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences. Dermatologic therapy 34 (1) (2020)
Martin Alan Menter, Petr Arenberger, Sigrid Balser, Stefan Beissert, Ashley Cauthen, Niklas Czeloth, Jennifer Soung, Sasha Jazayeri, Peter Weisenseel, Girish Jayadeva
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert opinion on biological therapy 21 (1) (2020)
Nicholas Nguyen, Annika S Silfvast-Kaiser, Jillian Frieder, Marcus Zaayman, Martin Alan Menter
Diffuse dermal angiomatosis of the breast. Proceedings (Baylor University. Medical Center) 33 (2) (2020)
Mark G Lebwohl, Andrew Blauvelt, Martin Alan Menter, Kim A Papp, Scott Guenthner, Radhakrishnan Pillai, Robert J Israel, Abby Jacobson
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American journal of clinical dermatology 20 (6) (2020)
Annika S Silfvast-Kaiser, Martin Alan Menter
How can we manage the safety concerns associated with the increase in biologics for psoriasis? Expert opinion on drug safety 19 (4) (2020)
Martin Alan Menter, Richard Warren
A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019. Dermatology and therapy 9 (1) (2019)
Boni Elewski, Martin Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan M Mendelsohn, Jeffrey Parno, Kenneth Gordon
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. The Journal of dermatological treatment 31 (8) (2019)
Martin Alan Menter, Diamant Thaçi, Jashin J Wu, William Abramovits, Francisco Kerdel, Dilek Arikan, Dianlin Guo, Arijit Ganguli, Mareike Bereswill, Anne Camez, Wendell C Valdecantos
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatology and therapy 7 (3) (2017)
Dario Kivelevitch, P Michel, Martin Alan Menter
Quality of life instruments in psoriasis clinical trials. The British journal of dermatology 176 (3) (2017)
Martin Alan Menter, Jennifer C Cather, Michael Jarratt, Xiangyi Meng, Adriana Guana, Judit Nyirady
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. Dermatology and therapy 6 (4) (2016)
Molly Campa, Bobbak Mansouri, Richard B Warren, Martin Alan Menter
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatology and therapy 6 (2) (2016)
Molly Campa, Bobbak Mansouri, Richard Warren, Martin Alan Menter
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatology and therapy 6 (1) (2015)